These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36198536)

  • 1. [Myeloproliferative neoplasms and vascular diseases].
    Ikeda K
    Rinsho Ketsueki; 2022; 63(9):1107-1114. PubMed ID: 36198536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.
    Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H
    J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils.
    Kimishima Y; Misaka T; Yokokawa T; Wada K; Ueda K; Sugimoto K; Minakawa K; Nakazato K; Ishida T; Oshima M; Koide S; Shide K; Shimoda K; Iwama A; Ikeda K; Takeishi Y
    Nat Commun; 2021 Oct; 12(1):6177. PubMed ID: 34702814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
    Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
    Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applied genomics in MPN presentation.
    Moliterno AR; Kaizer H
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):434-439. PubMed ID: 33275725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review].
    Zhang X; Yang J; Hao HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1627-1630. PubMed ID: 36208278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
    Zhang L; Dong H
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
    Moliterno AR; Ginzburg YZ; Hoffman R
    Blood; 2021 Mar; 137(9):1145-1153. PubMed ID: 33237986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms.
    Zhang H; Kafeiti N; Masarik K; Lee S; Yang X; Zheng H; Zhan H
    Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):1960-1974. PubMed ID: 38989576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms.
    Guy A; Garcia G; Gourdou-Latyszenok V; Wolff-Trombini L; Josserand L; Kimmerlin Q; Favre S; Kilani B; Marty C; Boulaftali Y; Labrouche-Colomer S; Mansier O; James C
    J Thromb Haemost; 2024 Jan; 22(1):172-187. PubMed ID: 37678548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations.
    Aoyama R; Kubota Y; Tara S; Wakita S; Yamaguchi H; Shimizu W; Takano H
    Int Heart J; 2022 Jul; 63(4):661-668. PubMed ID: 35831151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
    Chen E; Mullally A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
    Bhuria V; Baldauf CK; Schraven B; Fischer T
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
    Chen YX; Li Y; Zhang LY; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of HMGA2 in myeloproliferative neoplasms].
    Ikeda K
    Rinsho Ketsueki; 2018; 59(10):2067-2074. PubMed ID: 30305510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations.
    Tafesh L; Musgrave K; Roberts W; Plews D; Carey P; Biss T
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):490-493. PubMed ID: 29668539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.